Literature DB >> 6221669

Psychiatric syndromes in Huntington's disease.

E D Caine, I Shoulson.   

Abstract

Thirty patients with Huntington's disease, a genetically transmitted neuropsychiatric disorder that can be diagnosed reliably, were evaluated systematically for psychopathology, followed for extended periods, and treated with psychopharmacological medications when necessary. DSM-III criteria were used for establishing syndromic diagnoses. Twenty-four individuals demonstrated substantial behavioral abnormalities, including affective and schizophrenic syndromes, changes of personality, and disorders that could not be classified adequately. Pharmacotherapy was modestly beneficial in some cases. Consideration of the array of behavioral disturbances encountered in this pathogenetically unified disorder suggests that a dimensional approach to symptom classification might prove more useful heuristically than present typological methods.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6221669     DOI: 10.1176/ajp.140.6.728

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  28 in total

1.  Protein kinase C beta II mRNA levels decrease in the striatum and cortex of transgenic Huntington's disease mice.

Authors:  A S Harris; E M Denovan-Wright; L C Hamilton; H A Robertson
Journal:  J Psychiatry Neurosci       Date:  2001-03       Impact factor: 6.186

Review 2.  Executive control functions in degenerative dementias: a comparative review.

Authors:  L M Duke; A W Kaszniak
Journal:  Neuropsychol Rev       Date:  2000-06       Impact factor: 7.444

3.  Intelligence indices in people with a high/low risk for developing Huntington's disease.

Authors:  G M de Boo; A Tibben; J B Lanser; A Jennekens-Schinkel; J Hermans; M Vegter-van der Vlis; R A Roos
Journal:  J Med Genet       Date:  1997-07       Impact factor: 6.318

Review 4.  Magnetic resonance in patients with affective illness.

Authors:  W M McDonald; K R Krishnan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1992       Impact factor: 5.270

5.  Neuroanatomical Visualization of the Impaired Striatal Connectivity in Huntington's Disease Mouse Model.

Authors:  Dohee Kim; Jeha Jeon; Eunji Cheong; Dong Jin Kim; Hoon Ryu; Hyemyung Seo; Yun Kyung Kim
Journal:  Mol Neurobiol       Date:  2015-05-15       Impact factor: 5.590

6.  Modified electroconvulsive therapy for the treatment of refractory schizophrenia-like psychosis associated with Huntington's disease.

Authors:  Takeshi Nakano; Shinji Ono; Junji Yamaguchi; Ryu Sugimoto; Naohiro Yamaguchi; Yoshiro Morimoto; Tatsuya Kubo; Hiroki Ozawa; Naohiro Kurotaki
Journal:  J Neurol       Date:  2012-10-25       Impact factor: 4.849

7.  An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.

Authors:  Rodrigo A Fuentealba; Jayne Marasa; Marc I Diamond; David Piwnica-Worms; Conrad C Weihl
Journal:  Hum Mol Genet       Date:  2011-11-03       Impact factor: 6.150

8.  Psychiatric disorders in preclinical Huntington's disease.

Authors:  Camille L Julien; Jennifer C Thompson; Sue Wild; Pamela Yardumian; Julie S Snowden; Gwen Turner; David Craufurd
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-18       Impact factor: 10.154

9.  Behavioral Changes in Huntington Disease

Authors:  Jason Brandt
Journal:  Cogn Behav Neurol       Date:  2018-03       Impact factor: 1.600

10.  The nuclear receptor corepressor has organizational effects within the developing amygdala on juvenile social play and anxiety-like behavior.

Authors:  Heather M Jessen; Mira H Kolodkin; Meaghan E Bychowski; Catherine J Auger; Anthony P Auger
Journal:  Endocrinology       Date:  2010-01-05       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.